The Cureline Group, and palleos healthcare, today announced a strategic partnership to offer end-to-end solutions for medical innovation.
“This partnership will leverage both companies' complementary expertise and capabilities to support academic inventor teams, startups, and established companies in developing novel medical products from early-stage to clinical development, leading to a fully covered value chain that enables a ‘One-Stop-Shop' experience for our clients” – commented Prof. Dr. Ulrich Raeth Medical and Scientific Advisor at palleos healthcare. “We are excited to partner with palleos healthcare, a company that shares our vision of making innovation happen to overcome society’s health challenges,” said Dr. Olga Potapova, Founder and President of Cureline Group. “Together, we can offer our clients a comprehensive portfolio of services that covers the entire product development lifecycle, from product discovery, pre-clinical consulting and development to regulatory affairs and clinical trials, including data analysis and publishing.”
“Palleos healthcare is proud to join forces with Cureline,” stated Philip Raeth, Managing Director of palleos healthcare. “By combining our clinical trial services and our consulting expertise with Cureline’s human biospecimen (HBS) biobanking and laboratory services, we can provide our clients with customized solutions that meet their specific needs and accelerate their time to market.”
About Cureline, Inc., and Cureline Group of companies:
A global leader in commercial biobanking and translational research services with over 850 clients and 5,000+ projects completed. As a global precision and translational medicine contract research organization (CRO) since 2003 Cureline, Inc., (USA) together with other Cureline Group companies provides biobanking and HBS services in the preclinical phase and companion diagnostics development for clinical trials to the biopharmaceutical industry. Cureline Group management are experts in global regulatory affairs, custom protocol biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2021, UAB Cureline Baltic (Lithuania) is servicing our client’s needs in animal toxicology and preclinical efficacy studies in small animals with a focus on metastatic cancer, immunology and microbiota models. Contact: Olga Potapova, CEO, The Cureline Group,
firstname.lastname@example.org, +1 415-468-6400
About palleos healthcare GmbH:
palleos healthcare is an End-to-End Full CRO Service Provider with 50 highly experienced employees covering clinical research services in central Europe in small to large scale clinical studies ranging from phase I to Phase IV drug and medical device trials in various indications (academic and commercial). More than 10´000 patients at 300 sites were treated in various trials and indications managed by palleos healthcare. The results of those trials have been published in highly ranked journals and presented on conferences (e.g. ASCO Annual Meeting). palleos healthcare offers additionally drug development consulting services for biotech and medtech companies. By streamlining the early and pre-clinical development decisive milestones for exit and reinvestment are achieved earlier and more efficiently. As a certified partner with best-in-class players in the digital life science field (e.g. Veeva and Medidata) palleos healthcare also offers cloud-based services (data management platform, decentralized clinical trials) for the clinical drug and medical device development.
Contact: Heiko Bergmann, VP Sales & Strategy, palleos healthcare GmbH, email@example.com, +49 611 950 190 50
palleos healthcare is part of the Xlife Sciences AG, a leading European life sciences incubator and accelerator. Xlife Sciences is focused on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets.